Alnylam Pharmaceuticals (NASDAQ:ALNY) PT Raised to $220.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by Cantor Fitzgerald from $150.00 to $220.00 in a research report report published on Monday, Benzinga reports. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other analysts also recently commented on the company. Barclays raised their price objective on Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an overweight rating in a research report on Tuesday, June 25th. UBS Group raised their price target on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a buy rating in a report on Friday, June 28th. William Blair reaffirmed an outperform rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Citigroup lifted their target price on Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the company a buy rating in a research note on Tuesday, June 25th. Finally, HC Wainwright reissued a buy rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, June 24th. Eight analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of Moderate Buy and a consensus price target of $256.73.

Alnylam Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ:ALNY opened at $237.88 on Monday. The business has a 50 day moving average price of $197.28 and a 200 day moving average price of $172.50. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $263.73. The company has a market cap of $30.09 billion, a price-to-earnings ratio of -88.76 and a beta of 0.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. During the same quarter in the prior year, the business posted ($1.40) EPS. Alnylam Pharmaceuticals’s revenue was up 54.8% compared to the same quarter last year. Analysts anticipate that Alnylam Pharmaceuticals will post -3.99 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the sale, the director now owns 8,436 shares in the company, valued at $1,253,589.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the transaction, the director now owns 136 shares in the company, valued at $30,013.84. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Amy W. Schulman sold 21,700 shares of the stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now owns 8,436 shares in the company, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 74,450 shares of company stock valued at $15,287,984. Insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC grew its position in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares in the last quarter. Altitude Crest Partners Inc. acquired a new stake in Alnylam Pharmaceuticals during the first quarter worth approximately $30,000. Quent Capital LLC grew its position in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 123 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 12,513 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $52,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.